{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:15:18Z","timestamp":1788459318181,"version":"build-2803163510"},"reference-count":28,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"\n Objective<\/jats:title>\n To evaluate the efficacy and safety of three oliceridine different doses for oliceridine for patient-controlled analgesia (PCIA) in patients undergoing during total laparoscopic hysterectomy, following the premature termination of the planned sufentanil control arm.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n This prospective, randomized, double-blind trial was originally designed as a four-arm study. Due to operational challenges in patient recruitment and randomization within the single-center setting-specifically, significant reluctance among eligible patients to be randomized to receive a traditional opioid regimen when oliceridine was available, leading to unsustainable enrollment timelines\u2014the sufentanil control arm was prematurely terminated. The final analysis therefore focused on three oliceridine doses: 0.1, 0.35, and 0.5 mg\/kg, diluted to 100 ml with normal saline for 48-hour PCIA. The primary endpoint for sample size calculation was the incidence of postoperative nausea and vomiting (PONV) at 24 h. Efficacy and safety outcomes analyzed included: NRS pain scores (at rest and during cough), Ramsay sedation scores, incidence of rescue analgesia, various recovery indicators (time to first flatus, time to ambulation, QoR-15 scores), and opioid-related adverse events.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Compared to the low-dose group, the moderate- and high-dose groups demonstrated significant improvements in cough-pain scores and bolus press attempts (\u201cBolus press attempts\u201d were defined as the total number of patient-initiated demands for a supplemental dose, including attempts made within the lockout interval) (\n p<\/jats:italic>\n \u2009<\u20090.0083). Further comparison revealed that the moderate-dose group showed the best recovery outcomes, including shorter time to first flatus and ambulation, and higher QoR-15 scores. In contrast, although the high-dose group provided more potent analgesia, it was associated with a higher incidence of nausea, delayed flatus, and a significantly lower quality of recovery (QoR-15) score at 48 hours postoperatively compared to the moderate-dose group (\n p<\/jats:italic>\n \u2009<\u20090.0083).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Within the investigated PCA oliceridine dose range, the 0.35 mg\/kg dose promotes early recovery in patients undergoing laparoscopic total hysterectomy through effective analgesia and reduced nausea, representing the best balance between efficacy and safety among the tested oliceridine-specific regimens.<\/jats:p>\n <\/jats:sec>","DOI":"10.1371\/journal.pone.0357372","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:32:24Z","timestamp":1788456744000},"page":"e0357372","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of different doses of oliceridine for Patient-Controlled Intravenous Analgesia in patients undergoing Total Laparoscopic Hysterectomy"],"prefix":"10.1371","volume":"21","author":[{"given":"Jiaojiao","family":"Deng","sequence":"first","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baobao","family":"Ma","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaihua","family":"Wei","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wei","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Xie","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5581-4506","authenticated-orcid":true,"given":"Hong","family":"Zhang","sequence":"additional","affiliation":[{"name":"First Affiliated Hospital of Shihezi University School of Medicine","place":["Shihezi, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changxu","family":"Wang","sequence":"additional","affiliation":[{"name":"The Cancer Hospital Affiliated to Chongqing University","place":["Chongqing, China"],"department":["Department of Anesthesiology"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"issue":"1","key":"pone.0357372.ref001","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1185\/03007995.2013.860019","article-title":"Incidence, patient satisfaction, and perceptions of post-surgical pain: results from a US national survey","volume":"30","author":"TJ Gan","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"pone.0357372.ref002","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/JPR.S144066","article-title":"Poorly controlled postoperative pain: prevalence, consequences, and prevention","volume":"10","author":"TJ Gan","year":"2017","journal-title":"J Pain Res"},{"issue":"3","key":"pone.0357372.ref003","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.bja.2022.05.029","article-title":"Current approaches to acute postoperative pain management after major abdominal surgery: a narrative review and future directions","volume":"129","author":"K Pirie","year":"2022","journal-title":"Br J Anaesth"},{"issue":"1","key":"pone.0357372.ref004","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.atc.2004.11.013","article-title":"Consequences of inadequate postoperative pain relief and chronic persistent postoperative pain","volume":"23","author":"GP Joshi","year":"2005","journal-title":"Anesthesiol Clin North Am"},{"issue":"90003","key":"pone.0357372.ref005","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/keg497","article-title":"The burden of acute postoperative pain and the potential role of the COX-2-specific inhibitors","volume":"42","author":"J Stephens","year":"2003","journal-title":"Rheumatology"},{"issue":"16","key":"pone.0357372.ref006","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1007\/s40265-015-0482-y","article-title":"Laparoscopic surgery: a narrative review of pharmacotherapy in pain management","volume":"75","author":"S Sj\u00f6vall","year":"2015","journal-title":"Drugs"},{"issue":"2","key":"pone.0357372.ref007","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.suc.2014.10.002","article-title":"Postoperative pain control","volume":"95","author":"J Lovich-Sapola","year":"2015","journal-title":"Surg Clin North Am"},{"issue":"10","key":"pone.0357372.ref008","article-title":"Epidural analgesia versus patient-controlled intravenous analgesia for pain following intra-abdominal surgery in adults","author":"JH Salicath","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0357372.ref009","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.2147\/JPR.S363743","article-title":"Effectiveness of patient-controlled intravenous analgesia (PCIA) with sufentanil background infusion for post-cesarean analgesia: a randomized controlled trial","volume":"15","author":"Z Nie","year":"2022","journal-title":"J Pain Res"},{"key":"pone.0357372.ref010","article-title":"Opioid complications and side effects","volume":"11","author":"R Benyamin","year":"2008","journal-title":"Pain Physician"},{"issue":"3","key":"pone.0357372.ref011","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1124\/jpet.112.201616","article-title":"A G protein-biased ligand at the \u03bc-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine","volume":"344","author":"SM DeWire","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"pone.0357372.ref012","unstructured":"US Food & Drug Administration. FDA approves new opioid for intravenous use in hospitals, other controlled clinical settings media release; 2020. Available from: https:\/\/www.fda.gov\/"},{"issue":"1","key":"pone.0357372.ref013","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1213\/00000539-199901000-00016","article-title":"Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults","volume":"88","author":"PS Myles","year":"1999","journal-title":"Anesth Analg"},{"key":"pone.0357372.ref014","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.2147\/JPR.S137952","article-title":"A randomized, Phase IIb study investigating oliceridine (TRV130), a novel \u00b5-receptor G-protein pathway selective (\u03bc-GPS) modulator, for the management of moderate to severe acute pain following abdominoplasty","volume":"10","author":"N Singla","year":"2017","journal-title":"J Pain Res"},{"key":"pone.0357372.ref015","doi-asserted-by":"crossref","first-page":"927","DOI":"10.2147\/JPR.S171013","article-title":"APOLLO-1: a randomized placebo and active-controlled phase III study investigating oliceridine (TRV130), a G protein-biased ligand at the \u00b5-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy","volume":"12","author":"ER Viscusi","year":"2019","journal-title":"J Pain Res"},{"issue":"3","key":"pone.0357372.ref016","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1097\/ALN.0000000000000564","article-title":"Postoperative opioid-induced respiratory depression","volume":"122","author":"LA Lee","year":"2015","journal-title":"Anesthesiology"},{"key":"pone.0357372.ref017","unstructured":"revena Inc. Trevena announces FDA has set PDUFA date of August 7, 2020 for oliceridine media release]; 2020. Available from: https:\/\/www.trevena.com"},{"issue":"4","key":"pone.0357372.ref018","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/bja\/71.4.517","article-title":"Nausea and vomiting after gynaecological surgery: a meta-analysis of factors affecting their incidence","volume":"71","author":"CG Haigh","year":"1993","journal-title":"Br J Anaesth"},{"key":"pone.0357372.ref019","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2147\/JPR.S278279","article-title":"Oliceridine: a novel drug for the management of moderate to severe acute pain - a review of current evidence","volume":"14","author":"HS Tan","year":"2021","journal-title":"J Pain Res"},{"issue":"3","key":"pone.0357372.ref020","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/jcph.207","article-title":"First clinical experience with TRV130: pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"54","author":"DG Soergel","year":"2014","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"pone.0357372.ref021","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/sja.SJA_813_19","article-title":"Oliceridine and its potential to revolutionize GI endoscopy sedation","volume":"14","author":"B Goudra","year":"2020","journal-title":"Saudi J Anaesth"},{"issue":"4","key":"pone.0357372.ref022","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1358\/dot.2020.56.4.3107707","article-title":"Oliceridine, a G protein-selective ligand at the \u03bc-opioid receptor, for the management of moderate to severe acute pain","volume":"56","author":"TJ Gan","year":"2020","journal-title":"Drugs Today (Barc)"},{"issue":"18","key":"pone.0357372.ref023","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.2165\/00003495-200666180-00005","article-title":"Patient-controlled analgesia in the management of postoperative pain","volume":"66","author":"M Momeni","year":"2006","journal-title":"Drugs"},{"issue":"14","key":"pone.0357372.ref024","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.2165\/11634970-000000000-00000","article-title":"Opioid-induced bowel dysfunction: pathophysiology and management","volume":"72","author":"C Brock","year":"2012","journal-title":"Drugs"},{"issue":"13","key":"pone.0357372.ref025","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1056\/NEJMoa010564","article-title":"Selective postoperative inhibition of gastrointestinal opioid receptors","volume":"345","author":"A Taguchi","year":"2001","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0357372.ref026","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00268-018-4844-y","article-title":"Guidelines for perioperative care in elective colorectal surgery: enhanced recovery after surgery (ERAS\u00ae) society recommendations: 2018","volume":"43","author":"UO Gustafsson","year":"2019","journal-title":"World J Surg"},{"issue":"9","key":"pone.0357372.ref027","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1016\/j.pain.2014.06.011","article-title":"Biased agonism of the \u03bc-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers","volume":"155","author":"DG Soergel","year":"2014","journal-title":"Pain"},{"issue":"2","key":"pone.0357372.ref028","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s40122-021-00299-0","article-title":"Oliceridine exhibits improved tolerability compared to morphine at equianalgesic conditions: exploratory analysis from two phase 3 randomized placebo and active controlled trials","volume":"10","author":"GB Hammer","year":"2021","journal-title":"Pain Ther"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357372","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:32:29Z","timestamp":1788456749000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0357372"}},"subtitle":[],"editor":[{"given":"R&R","family":"PLOS","sequence":"first","affiliation":[{"name":"Public Library of Science","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":28,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0357372","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]}}}